Physician profile
Samarendra Chandel
NPI 1922096056
$5,071.65
in general payments reported to CMS, 2019-2025
21 companies · $721 in 2025
The $721 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $933 · 2020: $349 · 2021: $774 · 2022: $721 · 2023: $807 · 2024: $767 · 2025: $721.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,206 · Education: $88.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,205.99 |
| Education | $88.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $814.64 | 2019-2025 | |
| Boston Scientific Corporation | $585.66 | 2019-2025 | Watchman Flx, Versacross Access Solution |
| Janssen Pharmaceuticals, INC | $574.31 | 2020-2024 | Xarelto, Opsumit |
| Merck Sharp & Dohme LLC | $490.05 | 2022-2025 | Verquvo, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $460.22 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $327.84 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $266.44 | 2021-2025 | |
| Amgen INC. | $261.92 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $221.36 | 2019-2025 | Wainua, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $214.84 | 2020-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $196.28 | 2019-2024 | Lifevest |
| Amarin Pharma, INC. | $176.59 | 2020-2021 | |
| Alnylam Pharmaceuticals INC. | $105.24 | 2022-2023 | Onpattro |
| Actelion Pharmaceuticals US, INC. | $88.99 | 2024 | Uptravi, Opsumit |
| Abbott Laboratories | $73.16 | 2021-2025 | Cardiomems |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $50.34 | 2024-2025 | Wegovy |
| Edwards Lifesciences Corporation | $49.35 | 2020-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Lexicon Pharmaceuticals, INC. | $42.52 | 2023 | Inpefa |
| Baxter Healthcare | $25.97 | 2024 | Biopharma Sol - Contract Manuf |
| Sanofi-Aventis U.S. LLC | $25.12 | 2024 | |
| Recor Medical INC | $20.81 | 2025 | Paradise Ultrasound Renal Denervation System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samarendra Chandel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.